Case report · 16 Aug 2025
Case reportPublished 20 Oct 2020
Sequential Decitabine and Carboplatin Induced Stabilisation of Tumour Burden in a Patient with Immunotherapy-Resistant Metastatic Melanoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Despite significant progress in the treatment of metastatic melanoma in recent years with targeted and immune checkpoint inhibitor therapy, there is no effective treatment option once resistance to all of these treatments occurs. Here, we report stabilisation of disease in a patient with anti-PD1 immunotherapy resistance after sequential low-dose decitabine and carboplatin. Stable disease allowed for re-challenge with anti-PD1 immunotherapy. Stable disease with no disease progression was seen in a 47-year old Caucasian male diagnosed with metastatic melanoma with unknown primary who had progressed on previous BRAF/MEK inhibitors (dabrafenib and trametinib) and anti-PD1 immunotherapy (pembrolizumab) after 9 weeks on the novel Phase 2 study (PRIME001: Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma ACTRN12616000440426). The patient received two 4-week cycles of decitabine 7 mg/ m2 intravenous infusion (IVI)/day for 5 days (D1-D5) followed by Carboplatin AUC 5 IVI on day 8 (D8) and Week 3 and Week 4 no treatment. There were no toxicities >grade 2. Stable disease (RECIST 1.1) was recorded at week 9, the patient re-commenced Pembrolizumab and continued to have stable disease for a further 9 months. Tumour biopsies at baseline and at disease progression 9 months post re-commencing Pembrolizumab both showed high PD-L1 expression and moderate tumour infiltrating lymphocytes, predominately restricted to the tumour periphery. Genomic analysis identified high tumour mutation load and 4 mutations in common to the 2 biopsies. Peripheral immune cell profiles displayed an increase and stabilisation of CD4+ and CD8+ T-cells, particularly with the expression of CXCR6. Sequential decitabine and carboplatin is a feasible priming regime, with a tolerable safety profile for patients with advanced melanoma who are resistant to prior immunotherapy. The priming treatment limits the burden of disease to allow effective ongoing treatment with immune checkpoint inhibitors.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Oncology: Case Reports.
Research article · 30 Jul 2025
A Peculiar Case of Chronic Myelomonocytic Leukemia with Myelodysplastic Syndrome Overlap Presenting with Acute Renal Failure
Case report · 30 Jul 2025
Vertebral Giant Cell Tumor in a Young Male with Early Aggressive Recurrence and Pulmonary Metastases: A Rare Case Report and Literature Review
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Oncology: Case Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Andre Van der Westhuizen”
- BylineArticles whose byline prints “Naomi Knoblauch”
- BylineArticles whose byline prints “Moira C Graves”
- BylineArticles whose byline prints “Richard Levy”
- BylineArticles whose byline prints “Luke Hesson”
- BylineArticles whose byline prints “Ricardo E Vilain”
- BylineArticles whose byline prints “Nikola A Bowden”
